SAN DIEGO / Aug 26, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
| Last Trade: | US$75.11 |
| Daily Change: | 0.03 0.04 |
| Daily Volume: | 711,769 |
| Market Cap: | US$29.460B |
July 30, 2025 July 28, 2025 May 01, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
